Ambroxol to Slow Progression in Parkinson Disease

PHASE3RecruitingINTERVENTIONAL
Enrollment

330

Participants

Timeline

Start Date

February 25, 2025

Primary Completion Date

February 28, 2029

Study Completion Date

September 30, 2029

Conditions
Parkinson Disease
Interventions
DRUG

Ambroxol Hydrochloride (420mg)

Oral tablet

DRUG

Placebo

Oral tablet

Trial Locations (15)

Unknown

NOT_YET_RECRUITING

University Hospitals Birmingham, Birmingham

NOT_YET_RECRUITING

Southmead Hospital Bristol, Bristol

NOT_YET_RECRUITING

Addenbrookes NHS Trust, Cambridge

NOT_YET_RECRUITING

Western General Hospital, Edinburgh

NOT_YET_RECRUITING

Kings College London, London

NOT_YET_RECRUITING

Royal London Hospital, London

RECRUITING

University College London Hospital's, London

NOT_YET_RECRUITING

Newcastle, Newcastle

NOT_YET_RECRUITING

Northumbria, Newcastle upon Tyne

NOT_YET_RECRUITING

The John Radcliffe Hospital, Oxford

RECRUITING

Derriford Hospital, Plymouth

NOT_YET_RECRUITING

Fairfield General Hospital, Salford

RECRUITING

Salford Royal Hospital, Salford

NOT_YET_RECRUITING

Southampton General Hospital, Southampton

NOT_YET_RECRUITING

Prince Philip Hospital, Wales

All Listed Sponsors
lead

University College, London

OTHER